Sunshine Biopharma Inc Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Sunshine Biopharma Inc has an operating margin of -16.7%, meaning the company retains $-17 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -19.9% the prior year.
Sunshine Biopharma Inc's revenue surged 44.7% year-over-year to $34.9M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Sunshine Biopharma Inc carries a low D/E ratio of 0.30, meaning only $0.30 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 4.11, Sunshine Biopharma Inc holds $4.11 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Sunshine Biopharma Inc generated -$12.5M in operating cash flow, capex of $1.7M consumed most of it, leaving -$14.2M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Sunshine Biopharma Inc passes 1 of 9 financial strength tests. No profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.
For every $1 of reported earnings, Sunshine Biopharma Inc generates $2.44 in operating cash flow (-$12.5M OCF vs -$5.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Sunshine Biopharma Inc earns $-662.4 in operating income for every $1 of interest expense (-$5.8M vs $9K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
This page shows Sunshine Biopharma Inc (SBFM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Sunshine Biopharma Inc generated $34.9M in revenue in fiscal year 2024. This represents an increase of 44.7% from the prior year.
Sunshine Biopharma Inc's EBITDA was -$5.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 20.5% from the prior year.
Sunshine Biopharma Inc generated -$14.2M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 60.2% from the prior year.
Sunshine Biopharma Inc reported -$5.1M in net income in fiscal year 2024. This represents a decrease of 13.9% from the prior year.
Sunshine Biopharma Inc earned $-7.32 per diluted share (EPS) in fiscal year 2024. This represents an increase of 97.9% from the prior year.
Sunshine Biopharma Inc held $9.7M in cash against $0 in long-term debt as of fiscal year 2024.
Sunshine Biopharma Inc had 3M shares outstanding in fiscal year 2024. This represents an increase of 18313.5% from the prior year.
Sunshine Biopharma Inc's gross margin was 30.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 4.0 percentage points from the prior year.
Sunshine Biopharma Inc's operating margin was -16.7% in fiscal year 2024, reflecting core business profitability. This is up 3.2 percentage points from the prior year.
Sunshine Biopharma Inc's net profit margin was -14.7% in fiscal year 2024, showing the share of revenue converted to profit. This is up 4.0 percentage points from the prior year.
Sunshine Biopharma Inc invested $934K in research and development in fiscal year 2024. This represents a decrease of 49.7% from the prior year.
Sunshine Biopharma Inc spent $3.1M on share buybacks in fiscal year 2024, returning capital to shareholders by reducing shares outstanding. This represents an increase of 480.2% from the prior year.
Sunshine Biopharma Inc invested $1.7M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 1914.6% from the prior year.
SBFM Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.4M+0.1% | $9.4M+5.7% | $8.9M-7.2% | $9.6M+3.1% | $9.3M+23.4% | $7.5M-1.8% | $7.7M+28.9% | $6.0M |
| Cost of Revenue | $6.3M+6.0% | $6.0M-3.0% | $6.2M-5.1% | $6.5M-6.4% | $6.9M+33.9% | $5.2M+1.5% | $5.1M+28.9% | $4.0M |
| Gross Profit | $3.1M-10.2% | $3.4M+25.4% | $2.7M-11.7% | $3.1M+31.3% | $2.4M+0.1% | $2.4M-8.3% | $2.6M+29.0% | $2.0M |
| R&D Expenses | $119K-39.2% | $196K-8.8% | $215K+44.2% | $149K-65.8% | $436K+96.5% | $222K-72.8% | $816K+243.0% | $238K |
| SG&A Expenses | $4.2M-24.1% | $5.5M+36.0% | $4.0M-22.3% | $5.2M+42.9% | $3.6M-2.2% | $3.7M-0.7% | $3.7M+34.7% | $2.8M |
| Operating Income | -$1.1M+47.1% | -$2.1M-58.6% | -$1.3M+37.9% | -$2.1M-64.5% | -$1.3M+6.1% | -$1.4M-16.1% | -$1.2M-49.2% | -$779K |
| Interest Expense | $0 | $0 | $0+100.0% | -$41K-16692.7% | $245-99.5% | $49K+63.3% | $30K-21.8% | $39K |
| Income Tax | -$137K+34.3% | -$209K-420.8% | -$40K+68.8% | -$129K+62.5% | -$344K-1637.6% | $22K-89.9% | $220K+437.9% | $41K |
| Net Income | -$884K+50.1% | -$1.8M-50.1% | -$1.2M+45.3% | -$2.2M-336.6% | -$494K+61.5% | -$1.3M-2.7% | -$1.3M-91.9% | -$651K |
| EPS (Diluted) | N/A | $-0.82-86.4% | $-0.44 | N/A | $-43.48 | $-2.00 | N/A | N/A |
SBFM Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.5M-1.5% | $32.0M+9.5% | $29.2M-4.5% | $30.6M+4.3% | $29.3M-8.1% | $31.9M+16.6% | $27.3M-1.1% | $27.7M |
| Current Assets | $28.0M+0.4% | $27.9M+13.8% | $24.5M-5.7% | $26.0M+0.8% | $25.7M-10.7% | $28.8M+15.8% | $24.9M-2.1% | $25.4M |
| Cash & Equivalents | $9.3M-9.7% | $10.3M+26.8% | $8.1M-16.1% | $9.7M-15.8% | $11.5M-34.0% | $17.4M+7.0% | $16.3M-13.6% | $18.8M |
| Inventory | $14.1M+8.0% | $13.0M+9.8% | $11.9M+5.1% | $11.3M+32.8% | $8.5M+10.3% | $7.7M+34.2% | $5.7M+27.0% | $4.5M |
| Accounts Receivable | $4.2M+15.8% | $3.6M+4.1% | $3.4M-10.9% | $3.9M-2.6% | $4.0M+40.5% | $2.8M+10.8% | $2.6M+25.5% | $2.0M |
| Goodwill | N/A | N/A | N/A | $0 | N/A | N/A | $0 | N/A |
| Total Liabilities | $7.3M+16.0% | $6.3M-3.1% | $6.5M-8.1% | $7.1M+21.5% | $5.8M-17.9% | $7.1M+15.3% | $6.1M+8.0% | $5.7M |
| Current Liabilities | $6.7M+19.3% | $5.6M-3.3% | $5.8M-8.7% | $6.3M+19.2% | $5.3M-18.9% | $6.5M+17.7% | $5.6M+9.1% | $5.1M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $24.2M-5.8% | $25.7M+13.1% | $22.7M-3.4% | $23.5M0.0% | $23.5M-5.4% | $24.8M+17.0% | $21.2M-3.4% | $22.0M |
| Retained Earnings | -$72.9M-1.2% | -$72.0M-2.5% | -$70.2M-1.7% | -$69.0M-5.1% | -$65.7M-0.8% | -$65.2M-2.0% | -$63.9M-2.0% | -$62.7M |
SBFM Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$728K+42.8% | -$1.3M+25.7% | -$1.7M+49.8% | -$3.4M+25.5% | -$4.6M-43.7% | -$3.2M-18.4% | -$2.7M-488.2% | -$457K |
| Capital Expenditures | $8K-95.0% | $160K+2036.2% | $7K-92.7% | $103K-89.5% | $975K+1448.4% | $63K+116.5% | -$382K-4068.9% | $10K |
| Free Cash Flow | -$736K+48.7% | -$1.4M+16.7% | -$1.7M+51.0% | -$3.5M+36.7% | -$5.6M-70.9% | -$3.2M-5.7% | -$3.1M-557.9% | -$467K |
| Investing Cash Flow | -$118K+75.9% | -$492K-179.4% | -$176K+59.9% | -$439K+19.0% | -$542K+18.9% | -$669K-148.4% | -$269K-1527.6% | $19K |
| Financing Cash Flow | $76K-97.9% | $3.6M+967.7% | $338K-82.8% | $2.0M+6978.7% | -$29K-100.5% | $5.4M+17787.8% | -$31K+52.0% | -$64K |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Share Buybacks | $0 | $0 | $0 | $0 | $0-100.0% | $3.1M | $0 | N/A |
SBFM Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 32.6%-3.7pp | 36.4%+5.7pp | 30.7%-1.6pp | 32.2%+6.9pp | 25.3%-5.9pp | 31.2%-2.2pp | 33.4%+0.0pp | 33.4% |
| Operating Margin | -11.5%+10.3pp | -21.8%-7.3pp | -14.6%+7.2pp | -21.8%-8.1pp | -13.6%+4.3pp | -17.9%-2.8pp | -15.1%-2.1pp | -13.1% |
| Net Margin | -9.4%+9.4pp | -18.8%-5.6pp | -13.3%+9.2pp | -22.5%-17.2pp | -5.3%+11.7pp | -17.0%-0.7pp | -16.3%-5.3pp | -10.9% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -2.8%+2.7pp | -5.5%-1.5pp | -4.0%+3.0pp | -7.1%-5.4pp | -1.7%+2.3pp | -4.0%+0.5pp | -4.6%-2.2pp | -2.4% |
| Current Ratio | 4.20-0.8 | 5.00+0.7 | 4.25+0.1 | 4.11-0.7 | 4.86+0.4 | 4.41-0.1 | 4.48-0.5 | 5.00 |
| Debt-to-Equity | 0.30+0.1 | 0.24-0.0 | 0.29-0.0 | 0.30+0.1 | 0.25-0.0 | 0.290.0 | 0.29+0.0 | 0.26 |
| FCF Margin | -7.8%+7.4pp | -15.2%+4.1pp | -19.3%+17.3pp | -36.6%+23.0pp | -59.7%-16.6pp | -43.1%-3.1pp | -40.0%-32.2pp | -7.8% |
Similar Companies
Frequently Asked Questions
What is Sunshine Biopharma Inc's annual revenue?
Sunshine Biopharma Inc (SBFM) reported $34.9M in total revenue for fiscal year 2024. This represents a 44.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sunshine Biopharma Inc's revenue growing?
Sunshine Biopharma Inc (SBFM) revenue grew by 44.7% year-over-year, from $24.1M to $34.9M in fiscal year 2024.
Is Sunshine Biopharma Inc profitable?
No, Sunshine Biopharma Inc (SBFM) reported a net income of -$5.1M in fiscal year 2024, with a net profit margin of -14.7%.
What is Sunshine Biopharma Inc's earnings per share (EPS)?
Sunshine Biopharma Inc (SBFM) reported diluted earnings per share of $-7.32 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Sunshine Biopharma Inc's EBITDA?
Sunshine Biopharma Inc (SBFM) had EBITDA of -$5.6M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sunshine Biopharma Inc's gross margin?
Sunshine Biopharma Inc (SBFM) had a gross margin of 30.6% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Sunshine Biopharma Inc's operating margin?
Sunshine Biopharma Inc (SBFM) had an operating margin of -16.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Sunshine Biopharma Inc's net profit margin?
Sunshine Biopharma Inc (SBFM) had a net profit margin of -14.7% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Sunshine Biopharma Inc's free cash flow?
Sunshine Biopharma Inc (SBFM) generated -$14.2M in free cash flow during fiscal year 2024. This represents a -60.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sunshine Biopharma Inc's operating cash flow?
Sunshine Biopharma Inc (SBFM) generated -$12.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Sunshine Biopharma Inc's total assets?
Sunshine Biopharma Inc (SBFM) had $30.6M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Sunshine Biopharma Inc's capital expenditures?
Sunshine Biopharma Inc (SBFM) invested $1.7M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Sunshine Biopharma Inc spend on research and development?
Sunshine Biopharma Inc (SBFM) invested $934K in research and development during fiscal year 2024.
Does Sunshine Biopharma Inc buy back shares?
Yes, Sunshine Biopharma Inc (SBFM) spent $3.1M on share buybacks during fiscal year 2024, returning capital to shareholders by reducing shares outstanding.
How many shares does Sunshine Biopharma Inc have outstanding?
Sunshine Biopharma Inc (SBFM) had 3M shares outstanding as of fiscal year 2024.
What is Sunshine Biopharma Inc's current ratio?
Sunshine Biopharma Inc (SBFM) had a current ratio of 4.11 as of fiscal year 2024, which is generally considered healthy.
What is Sunshine Biopharma Inc's debt-to-equity ratio?
Sunshine Biopharma Inc (SBFM) had a debt-to-equity ratio of 0.30 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Sunshine Biopharma Inc's return on assets (ROA)?
Sunshine Biopharma Inc (SBFM) had a return on assets of -16.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Sunshine Biopharma Inc's cash runway?
Based on fiscal year 2024 data, Sunshine Biopharma Inc (SBFM) had $9.7M in cash against an annual operating cash burn of $12.5M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Sunshine Biopharma Inc's Piotroski F-Score?
Sunshine Biopharma Inc (SBFM) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sunshine Biopharma Inc's earnings high quality?
Sunshine Biopharma Inc (SBFM) has an earnings quality ratio of 2.44x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Sunshine Biopharma Inc cover its interest payments?
Sunshine Biopharma Inc (SBFM) has an interest coverage ratio of -662.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Sunshine Biopharma Inc?
Sunshine Biopharma Inc (SBFM) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.